Ethical obligation. Typical MBE IMS drivel rarely does this company ever tell the truth without being forced to by stockmarket reports. The rest is innuendo.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%